ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021

The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.

Stephen Opat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.